Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label, Two Parts Study in Chinese Patients With Advanced NSCLC Who Have Progressed Following Prior Therapy With an EGFR Tyrosine Kinase Inhibitor Agent

NCT02529995 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02529995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02529995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label, Two Parts Study in Chinese Patients With Advanced NSCLC Who Have Progressed Following Prior Therapy With an EGFR Tyrosine Kinase Inhibitor Agent
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
August 24, 2015
Completion date
September 27, 2019
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung with egfr mutation positive